Skin Diseases  >>  luminespib (AUY922)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
luminespib (AUY922) / Ligand
NCT01361945: AUY922 With Lapatinib and Letrozole for ER+ HER2+ Advanced Breast Cancer

Withdrawn
1/2
0
NA
AUY922, Intravenous drug
Texas Tech University Health Sciences Center, El Paso
Breast Cancer, Metastatic Breast Cancer, HER-2 Positive Breast Cancer, ER Positive Breast Cancer
08/12
08/12

Download Options